D-4517

N/A

Report date: 2025/05/12 14:50:42
NME

Base Information

Drug NameD-4517
Drug Alias NameHD-sunitinib analogMigaldendranibD-4517D-4517.2
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAngiogenesis inhibitorsVascular endothelial growth factor inhibitors
TargetsVascular endothelial growth factor
Therapy Area/IndicationsDiabetic macular oedemaMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAshvattha Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesAshvattha Therapeutics
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A